Redefining vaccination coverage and timeliness measures using electronic immunization registry data in low- and middle-income countries.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
22 03 2019
Historique:
received: 03 10 2018
revised: 07 12 2018
accepted: 01 02 2019
pubmed: 28 2 2019
medline: 13 8 2020
entrez: 28 2 2019
Statut: ppublish

Résumé

Vaccine coverage is routinely used as a performance indicator for immunization programs both at local and global levels. For many national immunization programs, there are challenges with accurately estimating vaccination coverage based on available data sources, however an increasing number of low- and middle-income countries (LMICs) have begun implementing electronic immunization registries to replace health facilities' paper-based tools and aggregate reporting systems. These systems allow for more efficient capture and use of routinely reported individual-level data that can be used to calculate dose-specific and cohort vaccination coverage, replacing the commonly used aggregate routine health information system data. With these individual-level data immunization programs have the opportunity to redefine performance measures to enhance programmatic decision-making at all levels of the health system. In this commentary, we discuss how measures for assessing vaccination status and program performance can be redefined and recalculated using these data when generated at the health facility level and the implications of the use and availability of electronic individual-level data.

Identifiants

pubmed: 30808566
pii: S0264-410X(19)30212-9
doi: 10.1016/j.vaccine.2019.02.017
pmc: PMC6420680
pii:
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1859-1867

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

Annu Rev Public Health. 2003;24:227-46
pubmed: 12668757
Lancet. 2003 Sep 27;362(9389):1022-7
pubmed: 14522532
Bull World Health Organ. 2005 Jul;83(7):503-10
pubmed: 16175824
Lancet. 2006 Mar 25;367(9515):965-6
pubmed: 16564344
Lancet. 2006 May 6;367(9521):1464-6
pubmed: 16679143
MMWR Morb Mortal Wkly Rep. 2006 Dec 15;55(49):1327-9
pubmed: 17167395
Lancet. 2008 Dec 13;372(9655):2031-46
pubmed: 19070738
Trop Med Int Health. 2009 Jan;14(1):2-10
pubmed: 19152556
Bull World Health Organ. 2009 Jul;87(7):535-41
pubmed: 19649368
MMWR Recomm Rep. 2011 Jan 28;60(2):1-64
pubmed: 21293327
Inform Prim Care. 2010;18(4):245-58
pubmed: 22040851
Wkly Epidemiol Rec. 2012 Jan 6;87(1):1-16
pubmed: 22242233
Hum Vaccin Immunother. 2013 Jun;9(6):1346-50
pubmed: 23422024
PLoS Med. 2013;10(5):e1001404
pubmed: 23667334
Public Health Rep. 2013 Nov-Dec;128(6):489-97
pubmed: 24179260
Rev Panam Salud Publica. 2014 May-Jun;35(5-6):453-7
pubmed: 25211576
Health Policy Plan. 2016 Feb;31(1):129-35
pubmed: 25887561
Vaccine. 2016 Jul 29;34(35):4103-4109
pubmed: 27349841
Matern Child Health J. 2017 Jan;21(1):29-35
pubmed: 27443650
Int J Environ Res Public Health. 2017 Jul 11;14(7):
pubmed: 28696387
Hum Vaccin Immunother. 2017 Sep 2;13(9):2102-2110
pubmed: 28696824
Mhealth. 2017 Jul 19;3:26
pubmed: 28828373
MMWR Morb Mortal Wkly Rep. 2017 Nov 03;66(43):1178-1181
pubmed: 29095809
MMWR Morb Mortal Wkly Rep. 2017 Nov 10;66(44):1226-1229
pubmed: 29121004
Vaccine. 2018 May 31;36(23):3260-3268
pubmed: 29731113
Vaccine. 2018 Dec 18;36(52):7923-7928
pubmed: 29983255
BMC Health Serv Res. 2018 Aug 8;18(1):621
pubmed: 30089497
Vaccine. 2018 Nov 29;36(50):7674-7681
pubmed: 30414780
Vaccine. 2018 Dec 18;36(52):7965-7974
pubmed: 30416017
Hum Vaccin Immunother. 2019;15(3):740-747
pubmed: 30457475

Auteurs

Samantha B Dolan (SB)

Dolan Consulting LLC; PATH, Seattle, USA; Department of Global Health, University of Washington, Seattle, USA. Electronic address: sdolan11@uw.edu.

Emily Carnahan (E)

PATH, Seattle, USA.

Jessica C Shearer (JC)

PATH, Seattle, USA.

Emily N Beylerian (EN)

PATH, Seattle, USA.

Jenny Thompson (J)

PATH, Seattle, USA.

Skye S Gilbert (SS)

PATH, Seattle, USA.

Laurie Werner (L)

PATH, Seattle, USA.

Tove K Ryman (TK)

Bill and Melinda Gates Foundation, Seattle, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH